Vol. 6 No. 3 (2026)
Reimbursement Reviews

Guselkumab (Tremfya)

decorative image of the issue cover

Published March 27, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses
    • Induction: Guselkumab (Tremfya) 200 mg/20 mL vial of sterile solution administered through IV infusion.
    • Maintenance: Guselkumab (Tremfya) 100 mg/1 mL pre-filled syringe, 100 mg/1 mL patient-controlled injector, 200 mg/2 mL pre-filled syringe, and 200 mg/2 mL pre-filled pen administered by subcutaneous injection.
  • Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis.